European regulators have approved Novo Nordisk's fast acting insulin Fiasp for the treatment of diabetes in adults, as the bolus component of basal-bolus therapy in combination with basal insulin and for continuous subcutaneous insulin infusion via an insulin pump.
Fiasp is an ultra-fast rapid-acting insulin that improves control of postprandial glucose excursions and has been developed for the treatment of people with both type I and type II diabetes.
The product is essentially a new formulation NovoRapid, in which two new excipients have been added to ensure earlier, greater and faster absorption, thereby providing earlier insulin action, the firm said.
"Fiasp is a new-generation mealtime insulin; it is an innovative faster formulation of insulin aspart that more closely mimics the physiological insulin response around meals," noted Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo.
"The incremental benefits with Fiasp are comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago", she added.
Novo said it expects to being rolling out the product in Europe in the first half of this year.